Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced the first subject has been dosed in ...
Long-acting RNA interference therapy for hypertension could shift blood pressure control from daily pill-taking to scheduled, ...
MedPage Today on MSN
Cemdisiran siRNA therapy demonstrates efficacy in myasthenia gravis
Investigational treatment improves outcomes without complete complement blockade ...
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...
SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the ...
Small interfering RNA (siRNA) molecules hold immense potential for treating diseases by silencing specific genes. Encapsulated in lipid nanoparticles (LNPs), siRNA can be delivered efficiently to ...
Researchers found a modified peptide carrier that was delivering the siRNA drug by adhering to and potentially moving along cell filopodia, leading to more efficient cell entry and improved gene ...
RNA interference is a gene regulatory mechanism in which the expression of specific genes is downregulated by endogenous microRNAs or by small interfering RNAs (siRNAs). Although siRNAs have broad ...
siMecA-AGO2 complex inhibits the translation of the mecA gene which encodes the penicillin-binding protein 2a (PBP2a), a protein at the heart of the drug-resistance phenotype in MRSA. By reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results